Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23573529 | 0.84 | OPRM1 (0.63) | KMT2ARAB9ANPC1MEN1GAA | |
| SCHEMBL23573478 | 0.84 | KMT2A (0.52) | KMT2ARAB9ANPC1L3MBTL1MAPK1 | |
| SCHEMBL23573339 | 0.84 | KMT2A (0.74) | KMT2ARAB9AEPHX2NPC1KDM4E | |
| SCHEMBL23573573 | 0.83 | MEN1 (0.66) | KMT2AKDM4EMEN1GAAL3MBTL1 | |
| SCHEMBL13450010 | 0.82 | KDM4E (0.70) | KMT2ARAB9AEPHX2NPC1KDM4E | |
| SCHEMBL23573310 | 0.80 | NPC1 (0.48) | KMT2ARAB9AEPHX2NPC1OPRM1 | |
| SCHEMBL13366272 | 0.79 | RAB9A (0.64) | KMT2ARAB9ANPC1KDM4EMEN1 | |
| SCHEMBL23462312 | 0.78 | KMT2A (0.76) | KMT2ARAB9AEPHX2NPC1MEN1 | |
| SCHEMBL23573512 | 0.78 | EPHX2 (0.67) | KMT2AEPHX2NPC1KDM4EMEN1 | |
| SCHEMBL10115870 | 0.78 | RAB9A (0.54) | KMT2ARAB9AEPHX2NPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ADORA2A, ENTPD1 | KMT2A 3173/4885RAB9A 2930/4885EPHX2 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.